PPAR gamma agonist
Prof. Frank M. Sacks discussing the role that Pioglitazone plays as a relevant #PPAR agonist
Management
▶ Watch videos on how best NASH and NAFLD can be managed.
View More ⏩PPAR gamma agonist
PPAR’s as Critical Regulators of Metabolism
Prof Roden, Germany explains why PPAR’s are interesting therapeutic targets not only to improve adipose tissue function but also for the liver. The approach can go beyond the improvement of liver function and aim at a more systemic approach with cardiovascular benefits.
PPAR alpha delta : what you need to know about the latest results
Prof Sacks, USA reviews the available data about PPAR alpha delta and the Elafibranor clinical program (RESOVE-IT). The interim results were presented earlier this year. They are somewhat disappointing (especially regarding the primary liver outcome).
PPAR alpha gamma dual agonists : what you need to know
Prof Sacks, USA reviews the available data about PPAR gamma agonist (Pioglitazone) especially data from the PROACTIVE study published in the Lancet in 2005
Lipids effects of PPARs by Prof. F. Sacks
Prof Sacks, USA summarises what we know about the PPARs lipid effects. If the strongest evidence is with PPAR-alpha agonists for which the main lipid effect is lowering triglycerids, the are interesting information to discuss about PPAR-delta (Seladelpar).
Role of PPARs (experimental paper) by Prof. F. Tacke
Prof. Frank Tacke discusses a paper in press in the Journal of Hepatology regarding the role of PPAR’s in experimental models and how these PPAR’s affect the progression of liver disease.
The role of a global holistic approach in NASH management: important messages
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
The role of comorbidities in NASH management: a holistic approach
Prof Jean-François Dufour, Switzerland, addresses the important problem of comorbidities in NASH management including diabetes, cardiovascular disease, cancer. This video was filmed in Boston during the Liver meeting 2019.
What can we expect from PPAR agonists in the treatment of NASH?
Prof Manal Abdelmalek, USA highlights the role that PPAR agonists could play in the treatment of NASH. This video was filmed in Boston during the Liver meeting 2019.
The role of PPARs in NASH fibrogenesis
Prof Gyongyi Szabo, USA discusses the role of PPARs in NASH fibrogenesis. This video was filmed in Boston during the Liver meeting 2019.
Prof Cusi sheds light on the new exciting information made public at the Liver meeting in Boston
The liver meeting has been fantastic. There’s a…
Prof Dufour Discusses Best Practices About the Diagnosis of NASH
Prof Dufour Discusses Best Practices About the Diagnosis of NASH